Methotrexate levels and outcome in osteosarcoma

Pediatric Blood and Cancer

Volumn 44, Issue 7, 2005, Pages 638-642

  Zelcer, Shayna ^a   Kellick, Michael ^a   Wexler, Leonard H ^a   Shi, Weiji ^a   Sankaran, Marie ^a   Lo, Sarah ^a   Healey, John ^a   Huvos, Andrew G ^a   Meyers, Paul A ^a   Gorlick, Richard ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Methotrexate; Necrosis; Osteosarcoma; Survival

Indexed keywords

BICARBONATE; CISPLATIN; CREATININE; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

ADOLESCENT; AREA UNDER THE CURVE; BONE NECROSIS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OSTEOSARCOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; FEMALE; HUMANS; MALE; METHOTREXATE; NECROSIS; OSTEOSARCOMA; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 20944450377     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20314     Document Type: Conference Paper

References (23)

1. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-989.
2. Jaffe N, Frei E III, Traggis D, et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:994-997.
3. Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteosarcoma. N Eng J Med 1974;291:998-1000.
4. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on event-free survival in patients with osteosarcoma of the extremity. N Eng J Med 1986;314:1600-1606.
5. Link MP, Gebhardt MC, Meyers PA. Osteosarcoma. In: Pizzo PA. Poplack DG, editors. Principles and practice of pediatric oncology. 4th edition. Philadelphia: Williams & Wilkins; 2002. pp 1051-1090.
6. Meyers PA, Heller G, Healey J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
7. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istitutuo Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990;65:2539-2553.
8. Ferrari S. Sassoli V, Orlandi M, et al. Serum methotrexate concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993;5:135-141.
9. Graf N, Winkler K, Betlemovic M. et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994;12: 1443-1451.
10. Delepine N, Delepine G, Cornille H. et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995;15:489-494.
11. Bacci G, Ferrari S, Delepine N. et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998; 16:658-663.
12. Bacci G, Ferrari S, Picci P, et al. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs. J Chemother 1996;8:472-478.
13. Leung S, Marshall GM, Al Mahr M, et al. Prognostic significance of chemotherapy dosage characteristics in children with osteogenic sarcoma. Med Pediatr Oncol 1997;28:179-182.
14. Delepine N, Delepine G, Jasmin C, et al. Importance of age and methotrexate dosage: Prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 1988;42:257-262.
15. Fleisher M, Schwartz MK. A common assay system for the measurement of antifolate analogs. Clin Chem 1992;38:609-610.
16. Pesce MA. Methotrexate. In: Pesce AJ, Kaplan LA, editors. Methods in clinical chemistry. St. Louis, CY: Mosby; 1987. pp 752-759.
17. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14-18.
18. Rosen G. Preoperative chemotherapy (neoadjuvant) for osteogenic sarcoma: A ten year experience. Orthopaedics 1985;8:659-664.
19. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-years experience. J Clin Oncol 1990;8:1988-1997.
20. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994;12:423-431.
21. Meyers PA, Heller G, Healey J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
22. Aquerreta I, Azucena A, Giraldez J, et al. Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatric Blood Cancer 2004;42:52-58.
23. Crews KR, Tieben L, Rodriguez-Galindo C, et al. High dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004;100:1724-1733.